SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about competition and a prolonged share-price decline. Many expect further weakness, while bulls argue pessimism is already priced in and see room for a rebound if results or the outlook are stronger than feared.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in bipolar mania met its primary and secondary endpoints, fueling buying interest and analyst optimism. Traders are debating whether the efficacy signal is strong enough given the modest placebo-adjusted improvement, higher discontinuation rates, and safety questions, contributing to volatile trading.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer

Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial OfficerPR NewswireRAMAT GAN, Israel, Oct. 13, 2026Expanded commercial...

Full Transcript: Pulsenmore H1 2026 Earnings Call

Pulsenmore (NASDAQ:PLSM) held its quarterly earnings conference call on Monday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial data and transcripts,read more...

Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore Expands Its Fertility Platform into the UK Pulsenmore Expands Its Fertility Platform into the UKPR NewswireOMER, Israel, Sept. 17, 2026 MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform...

Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring

Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring PR Newswire OMER, Israel, Sept. 8, 2026 The...

Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026

Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 PR Newswire OMER, Israel, Aug. 31, 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and...

Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026

Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026 Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026 PR Newswire OMER, Israel, Aug. 24, 2026 OMER, Israel...

Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring

Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring PR Newswire RAMAT...

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program

Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program PR Newswire RAMAT GAN, Israel, Aug. 17...

Transformational Deals and Breakthrough Data Take Center Stage

From a transformational merger and corporate restructuring at Twin Vee PowerCats, to encouraging Phase 2 clinical data from Q32 Bio, major oncology financing by Agenus, government-backed AI development at Pulsenmore, shareholder returns from LogProstyle, and new third-party testing validating Xeriant's advanced construction materials, this week's developments demonstrate the diverse catalysts capable of reshaping small-cap growth stories. $VEEE, $XERI, $PLSM, $LGPS, $QTTB, $AGEN

"One Million Dollars!" Why Pulsenmore's AI Project Could Be More Serious Than the Austin Powers Punchline

For fans of Austin Powers, the phrase "One million dollars!" became one of cinema's most memorable jokes, but Pulsenmore’s (NASDAQ:PLSM) newly announced $1 million government-backed artificial intelligence initiative could represent something far more meaningful than a punchline. The company has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, led by the Israel Innovation Authority and the Ministry of Health, to develop and clinically validate AI applications for its connected home ultrasound platform.

Pulsenmore Ltd. engages in research and development, production, marketing, and sale of self-scan ultrasound devices for remote clinical diagnosis and screening. It also offers a mobile app that guides the patient through a self-scan and enables online consolation with a clinician; as well as a clinician dashboard that allows clinicians to review scans and interacts with the patient remotely. The company was founded by Elazar Sonnenschein on October 27, 2014 and is headquartered in Omer, Israel.

Pulsenmore Ltd

Why Did PLSM Stock Surge More Than 200% Today? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The move will expand Pulsenmore’s presence in the U.S. maternal health market and create a growth opportunity.</li><li>The collaboration will particularly benefit to-be-mothers in remote U.S. regions who lack access to maternal care services.</li><li>The financial terms of the Pulsenmore-Ouma Health collaboration were not disclosed.</li></ul><p>Shares of Pulsenmore (PLSM) skyrocketed on Wednesday after the company’s home ultrasound solution was selected by Ouma Health for integration into its virtual maternity care platform.</p><p>At the time of writing, PLSM stock was up more than 200%.</p><h1 class="st-heading-1"><strong>What Does Ouma Health Do?</strong></h1><p>Privately held Ouma Health is the largest maternity telemedicine company in the U.S., specializing in virtual clinical care for women and guiding them from preconception through the end of their pregnancy journey, according to the company’s website.</p><p>Taking on Ouma as a partner will expand Pulsenmore’s presence in the U.S. maternal health market and create a growth opportunity by scaling its offering nationwide.</p><h1 class="st-heading-1"><strong>The Collaboration</strong></h1><p>As part of the collaboration, Ouma Health will use Pulsenmore's FDA-certified home ultrasound platform for its clients, particularly benefiting to-be-mothers in remote U.S. regions who lack access to such services.</p><p>"By partnering with Ouma Health, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care,” said Pulsenmore CEO Elazar Sonnenschein. “With 35% of U.S. counties classified as maternal care deserts, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers."</p><p>The financial terms of the collaboration were not disclosed.</p><h1 class="st-heading-1"><strong>What Do Retail Traders Think About PLSM?</strong></h1><p>On Stocktwits, retail sentiment on PLSM turned ‘extremely bullish’ from ‘neutral’ over the last 24 hours.</p><p>From going public on January 21 through the stock’s previous close on Tuesday, <a href="https://stocktwits.com/symbol/PLSM">PLSM</a> has lost more than half its value.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background. (Source: Getty Images)

Shares of Pulsenmore (PLSM) skyrocketed on Wednesday after the company’s home ultrasound solution was selected by Ouma Health for integration into its virtual maternity care platform.

Pulsenmore’s home ultrasound platform will be used by Ouma Health, the largest maternity telemedicine company in the U.S.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$1.82
Prev Close	$1.78
Open	$1.80
Dividend Yield	0.00%
50-Day Moving Average	$2.45
Beta	0.00
Avg. Volume	101,989.78
PE Ratio	-1.24

52-Week High	$12.97
52-Week Low	$1.71
Market Capitalization	$11.58M
EPS (Annual)	-$0.7134
Price to Book	0.71
Revenue Per Employee	$76,318.00

Feed

News

Sentiment

Fundamentals

Info

PLSM Fundamentals